XML 36 R17.htm IDEA: XBRL DOCUMENT
v3.22.4

Stockholders' Equity | 12 Months Ended
--- | ---
Dec. 31, 2022
Equity [Abstract] |
Stockholders' Equity | Stockholders’ Equity Share-based Compensation Expense The following table summarizes share-based compensation expense from continuing operations (in thousands):
| December 31,
| 2022 |  | 2021(a) |  | 2020(a)
Share-based compensation expense as a component of: |  |  |  |  |
Research and development expenses | $ | 10,970 |  |  | $ | 9,341 |  |  | $ | 8,513 |
General and administrative expenses | 39,911 |  |  | 19,985 |  |  | 16,612 |
| $ | 50,881 |  |  | $ | 29,326 |  |  | $ | 25,125 |
(a) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation. Conversion and Modification of Equity Awards Outstanding at Separation Date In connection with the OmniAb Separation on November 1, 2022, under the provisions of the existing plans, we adjusted our outstanding equity awards in accordance with the Merger Agreement to preserve the intrinsic value of the awards immediately before and after the Distribution. Upon the Distribution, employees holding stock options, restricted stock units and performance restricted stock units denominated in pre-Distribution Ligand stock received a number of otherwise-similar awards either in post-Distribution Ligand stock or in a combination of post-Distribution Ligand stock and OmniAb stock based on conversion ratios outlined for each group of employees in the Merger Agreement that we entered into in connection with the Distribution. The equity awards that were granted prior to March 2, 2022 were converted under the shareholder method, wherein employees holding outstanding equity awards received equity awards in both Ligand and OmniAb. For equity awards granted after March 2, 2022, for Ligand employees, the number of awards that were outstanding at the Separation were proportionately adjusted into post-Distribution Ligand stock to maintain the aggregate intrinsic value of the awards at the date of the Separation; for OmniAb employees, the number of awards that were outstanding at the Separation were proportionately adjusted into post-Distribution OmniAb stock to maintain the aggregate intrinsic value of the awards at the date of the Separation. The conversion ratio was determined based on the relative values of Ligand common stock in the “regular way” and “ex-distribution” markets during the five-trading day period prior to the closing of the business combination. These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. Additionally, we will not incur any future compensation cost related to equity awards held by OmniAb employees and directors. We will incur future compensation cost related to OmniAb equity awards held by our employees. Stock Plans In June 2022, our stockholders approved the amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan (the “2002 Plan”). The amended and restated 2002 Plan, which is referred to herein as the “Restated Plan” was amended to increase the shares available for issuance by 1.0 million. On July 29, 2022, our board of directors (the “Board”) approved the Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan (the “2022 Inducement Plan”). The terms of the 2022 Inducement Plan are substantially similar to the terms of the Restated Plan with the exception that incentive stock options may not be issued under the 2022 Inducement Plan and awards under the 2022 Inducement Plan may only be issued to eligible recipients under the applicable Nasdaq Listing Rules. The 2022 Inducement Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Board has initially reserved 300,000 shares of the Company’s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. As of December 31, 2022, there were 1.3 million shares available for future option grants or direct issuance under the Restated Plan and the 2022 Inducement Plan. Following is a summary of our stock option plan activity and related information:
| Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term in Years |  | Aggregate Intrinsic Value (In thousands)
Balance at January 1, 2020 | 1,956,379 |  |  | $ | 77.54 |  |  | 5.45 |  | $ | 72,002 |
Granted | 806,300 |  |  | $ | 92.93 |  |  |  |  |
Exercised | (156,845) |  |  | $ | 21.26 |  |  |  |  |
Forfeited | (44,012) |  |  | $ | 91.30 |  |  |  |  |
Balance at December 31, 2020 | 2,561,822 |  |  | $ | 85.59 |  |  | 6.09 |  | $ | 59,033 |
Exercisable at December 31, 2020 | 1,611,830 |  |  | $ | 76.05 |  |  | 4.54 |  | $ | 53,286 |
Options vested and expected to vest as of December 31, 2020 | 2,561,822 |  |  | $ | 85.59 |  |  | 6.09 |  | $ | 59,033 |
Granted | 393,589 |  |  | $ | 159.12 |  |  |  |  |
Exercised | (619,731) |  |  | $ | 54.28 |  |  |  |  |
Forfeited | (136,082) |  |  | $ | 110.83 |  |  |  |  |
Balance at December 31, 2021 | 2,199,598 |  |  | $ | 106.00 |  |  | 6.34 |  | $ | 113,302 |
Exercisable at December 31, 2021 | 1,391,952 |  |  | $ | 98.16 |  |  | 5.12 |  | $ | 80,849 |
Options vested and expected to vest as of December 31, 2021 | 2,199,598 |  |  | $ | 106.00 |  |  | 6.34 |  | $ | 113,302 |
Granted | 863,245 |  |  | $ | 91.34 |  |  |  |  |
Exercised | (34,941) |  |  | $ | 38.56 |  |  |  |  |
Forfeited | (40,069) |  |  | $ | 78.46 |  |  |  |  |
Balance at October 31, 2022 | 2,987,833 |  |  | $ | 102.92 |  |  | 0 |  | $ | 14,835 |
Exercisable at October 31, 2022 | 1,769,629 |  |  | $ | 102.38 |  |  | 0 |  | $ | 13,722 |
Options vested and expected to vest as of October 31, 2022, before Separation and Regrant | 2,987,833 |  |  | $ | 102.92 |  |  | 0 |  | $ | 14,835 |
Cancellation due to Separation, Before Regrant | (2,987,833) |  |  |  |  |  |  |
Balance at November 1, 2022, Before Regrant | — |  |  |  |  |  |  |
Granted (1) | 3,584,760 |  |  | $ | 60.10 |  |  |  |  |
Exercised | (50,449) |  |  | $ | 30.24 |  |  |  |  |
Forfeited | (542,838) |  |  | $ | 56.20 |  |  |  |  |
Balance at December 31, 2022 | 2,991,473 |  |  | $ | 61.31 |  |  | 6.07 |  | $ | 30,477 |
Exercisable at December 31, 2022 | 1,559,662 |  |  | $ | 60.83 |  |  | 4.51 |  | $ | 17,951 |
Options vested and expected to vest as of December 31, 2022 | 2,991,473 |  |  | $ | 61.31 |  |  | 6.07 |  | $ | 30,477 |
(1) Options granted primarily relate to the modifications in connection with the Separation which resulted in new stock option grants at the modification date fair value. The weighted-average grant-date fair value of all stock options granted during 2022, 2021 and 2020 was $28.90, $80.08, and $41.39 per share, respectively. The total intrinsic value of all options exercised during 2022, 2021 and 2020 was approximately $4.6 million, $77.3 million, and $11.9 million, respectively. Cash received from options exercised, net of fees paid, in 2022, 2021 and 2020 was $2.6 million, $33.0 million and $2.5 million, respectively. Following is a further breakdown of the options outstanding as of December 31, 2022:
Range of exercise prices | Options outstanding |  | Weighted average remaining life in years |  | Weighted average exercise price |  | Options exercisable |  | Weighted average exercise price
$12.78-$43.36 | 395,660 |  |  | 2.32 |  | $ | 35.76 |  |  | 366,426 |  |  | $ | 35.44 |
$46.20-$52.78 | 279,405 |  |  | 6.63 |  | $ | 50.24 |  |  | 122,734 |  |  | $ | 50.18 |
$52.84-$52.84 | 580,629 |  |  | 7.59 |  | $ | 52.84 |  |  | 88,647 |  |  | $ | 52.84 |
$54.81-$57.22 | 391,280 |  |  | 6.47 |  | $ | 56.24 |  |  | 198,283 |  |  | $ | 56.26 |
$58.28-$67.03 | 477,042 |  |  | 5.78 |  | $ | 64.11 |  |  | 274,719 |  |  | $ | 62.90 |
$67.24-$69.70 | 403,187 |  |  | 6.93 |  | $ | 68.98 |  |  | 207,981 |  |  | $ | 68.60 |
$70.04-$93.12 | 254,738 |  |  | 5.56 |  | $ | 87.72 |  |  | 204,332 |  |  | $ | 89.21 |
$99.80-$99.80 | 3,389 |  |  | 5.84 |  | $ | 99.80 |  |  | 3,389 |  |  | $ | 99.80 |
$103.42-$103.42 | 193,177 |  |  | 7.26 |  | $ | 103.42 |  |  | 80,185 |  |  | $ | 103.42 |
$114.15-$114.15 | 12,966 |  |  | 5.47 |  | $ | 114.15 |  |  | 12,966 |  |  | $ | 114.15 |
| 2,991,473 |  |  | 6.07 |  | $ | 61.31 |  |  | 1,559,662 |  |  | $ | 60.83 |
The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:
| Year Ended December 31,
| 2022 |  | 2021 |  | 2020 |
Risk-free interest rate | 1.4%-4.3% |  | 0.4%-1.2% |  | 0.2%-1.4% |
Expected volatility | 49%-55% |  | 47%-63% |  | 47%-71% |
Expected term | 2.0 to 6.5 years |  | 4.7 to 6.3 years |  | 4.7 to 5.1 years |
As of December 31, 2022, there was $32.7 million of total unrecognized compensation cost related to non-vested stock options under the 2002 Plan. That cost is expected to be recognized over a weighted average period of 2.7 years. As of December 31, 2022, there was $4.8 million of total unrecognized compensation cost related to non-vested OmniAb stock options received upon aforementioned spin-off conversion. That cost is expected to be recognized over a weighted average period of 1.8 years. Restricted Stock Activity The following is a summary of our restricted stock activity and related information:
| Shares |  | Weighted-Average Grant Date Fair Value
Outstanding at January 1, 2020 | 147,259 |  |  | $ | 125.11 |
Granted | 111,306 |  |  | $ | 89.73 |
Vested | (52,363) |  |  | $ | 121.69 |
Forfeited | — |  |  | $ | — |
Outstanding at January 1, 2021 | 206,202 |  |  | $ | 106.88 |
Granted | 167,292 |  |  | $ | 169.63 |
Vested | (98,501) |  |  | $ | 125.59 |
Forfeited | (10,850) |  |  | $ | 141.85 |
Outstanding at December 31, 2021 | 264,143 |  |  | $ | 138.21 |
Granted | 260,577 |  |  | $ | 89.99 |
Vested | (138,867) |  |  | $ | 120.57 |
Forfeited | (19,383) |  |  | $ | 58.45 |
Outstanding at October 31, 2022, before Separation and Regrant | 366,470 |  |  | $ | 114.83 |
Forfeited due to Separation, Before Regrant | (366,470) |  |  |
Balance at November 1, 2022, Before Regrant | — |  |  |
Granted | 424,473 |  |  | $ | 75.61 |
Vested | (73,385) |  |  | $ | 75.17 |
Forfeited | (2,635) |  |  | $ | 89.05 |
Balance at December 31, 2022 | 348,453 |  |  | $ | 75.60 |
As of December 31, 2022, unrecognized compensation cost related to non-vested stock awards under the 2002 Plan amounted to $12.4 million. That cost is expected to be recognized over a weighted average period of 1.7 years. As of December 31, 2022, there was $1.2 million of total unrecognized compensation cost related to non-vested OmniAb stock awards received upon aforementioned spin-off conversion. That cost is expected to be recognized over a weighted average period of 1.0 years. Employee Stock Purchase Plan As of December 31, 2022, 35,881 shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were 8,479, 8,448 and 6,455 shares issued under the ESPP in 2022, 2021 and 2020, respectively. Share Repurchases In September 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $500.0 million of our common stock from time to time over a period of up to three years. This repurchase program expired in September 2022. During the year ended December 31, 2022 and 2021, we did not repurchase any common stock, respectively. During the year ended December 31, 2020, we repurchased 934,079 shares for $78.0 million. At-the Market Equity Offering Program On September 30, 2022, we filed a registration statement on Form S-3 (the “Shelf Registration Statement”), which became automatically effective upon filing, covering the offering of common stock, preferred stock, debt securities, warrants and units. On September 30, 2022, we also entered into an At-The-Market Equity Offering Sales Agreement (the “Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated (the “Agent”), under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $100.0 million in “at the market” offerings through the Agent (the “ATM Offering”). The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $100.0 million of our common stock from time to time through the ATM Offering. The shares to be sold under the Sales Agreement may be issued and sold pursuant to the Shelf Registration Statement. To date, we have not issued any shares of common stock in the ATM Offering.
Balance Sheet Account Details | Balance Sheet Account Details Short-term Investments Excluding our investments in Viking, the following table summarizes the various investment categories at December 31, 2022 and 2021 (in thousands):
| Cost |  | Gross unrealized gains |  | Gross unrealized losses |  | Estimated fair value
December 31, 2022 |  |  |  |  |  |  |
Short-term investments |  |  |  |  |  |  |
Mutual Funds | $ | 81,815 |  |  | $ | — |  |  | $ | (1050) |  |  | $ | 80,765 |
Bank deposits | 5,012 |  |  | 2 |  |  | (34) |  |  | 4,980 |
Commercial paper | 7,211 |  |  | 3 |  |  | — |  |  | 7,214 |
Corporate bonds | 6,701 |  |  | 13 |  |  | (58) |  |  | 6,656 |
Corporate equity securities | 5,807 |  |  | 262 |  |  | (4,239) |  |  | 1,830 |
U.S. government securities | 2,232 |  |  | — |  |  | (70) |  |  | 2,162 |
Warrants | — |  |  | 135 |  |  | — |  |  | 135 |
| $ | 108,778 |  |  | $ | 415 |  |  | $ | (5,451) |  |  | $ | 103,742 |
December 31, 2021 |  |  |  |  |  |  |
Short-term investments |  |  |  |  |  |  |
Mutual fund | $ | 152,136 |  |  | $ | — |  |  | $ | (249) |  |  | $ | 151,887 |
Bank deposits | 63,389 |  |  | 13 |  |  | (21) |  |  | 63,381 |
Commercial paper | 36,008 |  |  | 2 |  |  | (12) |  |  | 35,998 |
Corporate bonds | 29,308 |  |  | 17 |  |  | (38) |  |  | 29,287 |
Corporate equity securities | 5,807 |  |  | 402 |  |  | (2,027) |  |  | 4,182 |
U.S. government securities | 5,577 |  |  | — |  |  | (23) |  |  | 5,554 |
Warrants | — |  |  | 408 |  |  | — |  |  | 408 |
| $ | 292,225 |  |  | $ | 842 |  |  | $ | (2,370) |  |  | $ | 290,697 |
Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities, and realized gain (loss) from available-for-sale debt securities. The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):
| December 31, 2022
| Amortized Cost |  | Fair Value
Within one year | $ | 57,158 |  |  | $ | 57,036 |
After one year through five years | 2,794 |  |  | 2,769 |
Total | $ | 59,952 |  |  | $ | 59,805 |
The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):
| Less than 12 months |  | 12 months or greater |  | Total
| Gross Unrealized Losses |  | Estimated Fair Value |  | Gross Unrealized Losses |  | Estimated Fair Value |  | Gross Unrealized Losses |  | Estimated Fair Value
December 31, 2022 |  |  |  |  |  |  |  |  |  |  |
Bank deposits | $ | (34) |  |  | $ | 2,470 |  |  | $ | — |  |  | $ | — |  |  | $ | (34) |  |  | $ | 2,470 |
Corporate bonds | (21) |  |  | 3,887 |  |  | (37) |  |  | 947 |  |  | (58) |  |  | 4,834 |
Commercial paper | — |  |  | 3,836 |  |  | — |  |  | — |  |  | — |  |  | 3,836 |
U.S. Government Securities | (70) |  |  | 2,161 |  |  | — |  |  | — |  |  | (70) |  |  | 2,161 |
Total | $ | (125) |  |  | $ | 12,354 |  |  | $ | (37) |  |  | $ | 947 |  |  | $ | (162) |  |  | $ | 13,301 |
December 31, 2021 |  |  |  |  |  |  |  |  |  |  |
Bank deposits | $ | (13) |  |  | $ | 20,008 |  |  | $ | — |  |  | $ | — |  |  | $ | (13) |  |  | $ | 20,008 |
Corporate bonds | (15) |  |  | 27,252 |  |  | (5) |  |  | 2,996 |  |  | (20) |  |  | 30,248 |
Commercial paper | (6) |  |  | 6,689 |  |  | (32) |  |  | 10,125 |  |  | (38) |  |  | 16,814 |
U.S. Government Securities | — |  |  | — |  |  | (23) |  |  | 5,553 |  |  | (23) |  |  | 5,553 |
Total | $ | (34) |  |  | $ | 53,949 |  |  | $ | (60) |  |  | $ | 18,674 |  |  | $ | (94) |  |  | $ | 72,623 |
Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of 12 positions which were in an unrealized loss position as of December 31, 2022. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. We do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of the amortized cost basis. Accordingly, no credit losses were recognized for the twelve months ended December 31, 2022. Property and equipment are stated at cost and consists of the following (in thousands):
| December 31,
| 2022 |  | 2021
Lab and office equipment | $ | 14,172 |  |  | $ | 13,417 |
Leasehold improvements | 7,446 |  |  | 5,265 |
Computer equipment and software | 989 |  |  | 924 |
| 22,607 |  |  | 19,606 |
Less accumulated depreciation and amortization | (10,125) |  |  | (6,415) |
| $ | 12,482 |  |  | $ | 13,191 |
Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from three to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $3.8 million, $2.4 million, and $1.5 million was recognized for the twelve months ended December 31, 2022, 2021, and 2020, respectively, and was included in operating expenses. Goodwill and identifiable intangible assets consist of the following (in thousands):
| December 31,
| 2022 |  | 2021
Indefinite-lived intangible assets |  |  |
Goodwill | $ | 105,673 |  |  | $ | 105,673 |
Definite-lived intangible assets |  |  |
Complete technology | 55,211 |  |  | 55,211 |
Less: Accumulated amortization | (22,560) |  |  | (18,916) |
Trade name | 2,642 |  |  | 2,642 |
Less: Accumulated amortization | (1,577) |  |  | (1,444) |
Customer relationships | 29,600 |  |  | 29,600 |
Less: Accumulated amortization | (17,670) |  |  | (16,184) |
Contractual relationships | 362,000 |  |  | 362,000 |
Less: Accumulated amortization | (65,191) |  |  | (36,218) |
Total goodwill and other identifiable intangible assets, net | $ | 448,128 |  |  | $ | 482,364 |
Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20 years. Amortization expense of $34.2 million, $34.2 million, and $11.6 million was recognized for the years ended December 31, 2022, 2021, and 2020, respectively. Estimated amortization expense for the years ending December 31, 2023 through 2027 is $34.1 million per year. For each of the years ended December 31, 2022, 2021, and 2020, there was no material impairment of intangible assets with finite lives. Accrued liabilities consist of the following (in thousands):
| December 31,
| 2022 |  | 2021
Compensation | $ | 6,201 |  |  | $ | 6,532 |
Professional fees | 662 |  |  | 2,046 |
Amounts owed to former licensees | 3,989 |  |  | 630 |
Royalties owed to third parties | 12 |  |  | 149 |
Return reserve and customer refunds | — |  |  | 2,420 |
Acquisition related liabilities | — |  |  | 1,000 |
Subcontractor | — |  |  | 1,759 |
Supplier | 634 |  |  | 848 |
Other | 4,183 |  |  | 2,195 |
| $ | 15,681 |  |  | $ | 17,579 |
Contingent liabilities: In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders. In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones. For CVRs associated with the Pfenex, see “Note (4), Acquisitions” for more information. The following table summarizes roll-forward of contingent liabilities as of December 2022 and 2021 (in thousands):
| December 31, 2020 |  | Payments | Fair Value Adjustment | December 31, 2021 |  |  | Payments | Fair Value Adjustment | Repurchases | December 31, 2022
Cydex | $ | 507 |  |  | $ | (50) |  | $ | (108) |  | $ | 349 |  |  |  | $ | — |  | $ | (265) |  | $ | — |  | $ | 84 |
Metabasis | 3,822 |  |  | — |  | (464) |  | 3,358 |  |  |  | — |  | 71 |  | — |  | 3,429 |
Pfenex | 37,600 |  |  | — |  | (37,600) |  | — |  |  |  | — |  | — |  | — |  | — |
Total | $ | 41,929 |  |  | $ | (50) |  | $ | (38,172) |  | $ | 3,707 |  |  |  | $ | — |  | $ | (194) |  | $ | — |  | $ | 3,513 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI https://asc.fasb.org/topic&trid=2208762 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (i) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 50 -Paragraph 6 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI https://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration